Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,314 shares of the biopharmaceutical company’s stock after buying an additional 6,485 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Regeneron Pharmaceuticals were worth $21,355,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares in the last quarter. Northern Trust Corp boosted its position in shares of Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after purchasing an additional 34,326 shares in the last quarter. Morgan Stanley increased its holdings in shares of Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after purchasing an additional 25,792 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock valued at $754,422,000 after purchasing an additional 30,050 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Regeneron Pharmaceuticals by 3.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock worth $545,081,000 after buying an additional 22,558 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on REGN shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $989.36.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $2.62 during midday trading on Thursday, reaching $975.59. The company’s stock had a trading volume of 98,551 shares, compared to its average volume of 484,656. The company has a 50 day moving average price of $942.52 and a 200 day moving average price of $906.25. The company has a market cap of $107.50 billion, a price-to-earnings ratio of 28.90, a price-to-earnings-growth ratio of 2.01 and a beta of 0.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Insider Activity at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,095 shares of company stock valued at $32,261,016. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.